01952

21.7605.23%
YW

Ying Woo

CFO, President & Executive Director

Mr. Ying Woo, also known as Ian, is Director of NovaBridge Biosciences from October 2025. Mr. Woo is Chief Financial Officer and President at Everest Medicines Limited since June 2018 and has been its Director since December 31, 2018 and also has interim duties and responsibilities of the Chief Executive Officer from August 26, 2022. Mr. Woo is also a director of Everest Medicines II Limited and Everest Medicines (US) Limited. He served as an Independent Director at Prenetics Global Limited since 2022 until May 17, 2024. He has been the President and Chief Financial Officer at Everest Medicines since June 24, 2018. From June 2018 to June 2019, he was a Managing Director at C-Bridge Capital. Before joining Everest Medicines, Mr. Woo was a managing director in the global healthcare group at Lazard, one of the world's premier financial advisory and asset management firms. He covered global biopharma companies and led Lazard's healthcare efforts in Greater China. Mr. Woo served as a managing director in the healthcare advisory team at Lazard Frères & Co. LLC (“LFNY”). Mr. Woo joined Lazard in March 2005, other than from 2012 to 2016. From January 2012 to June 2016 during which period he worked at Lazard Asia (Hong Kong) Limited, LFNY’s Hong Kong office and an SFC licensed corporation. Mr. Woo holds a Master of Business Administration from Columbia University Business School in May 2003, a M.Sc in Molecular and Cellular Biology from Columbia University Graduate School of Arts Sciences in May 1998 and a B.Sc in Biology from Tufts University in May 1994. Mr. Woo was also a student at Harvard University Graduate School of Arts Sciences and conducted research at Harvard Medical School and Brigham and Women's Hospital, where he was an author on multiple published papers.

Positions